Case Study: Cost Analysis and Emission and Analysis of a 100mw Grid-Connected Wind Energy System Using Retscreen Expert Simulation Software
Journal of Technology Research · 15.06.2024 · 2 (1) · 1-6
DOI: 10.26629/jtr.2024.01 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Technology Research, online erschienen am 15.06.2024. Verfasst von Almotaz bellah Abouda.
Abstract (Originalsprache)
This research demonstrates the feasibility of using wind energy as a clean source for electricity generation. The study was conducted at a wind farm in the eastern city of Misrata, using the RETScreen program for performance and cost evaluation. Wind is considered a renewable and non-polluting source, and the research aims to compare the efficiency of the wind farm with gas-fired power plants. The RETScreen program was used to determine the suitable location for establishing a wind farm based on the appropriate wind speed and selecting the appropriate turbine from the program's library. Multiple results were obtained, including speed, power, and energy curves. The research also investigated the connection of the wind farm to the public electricity grid and analyzed the costs and carbon emissions associated with the farm.
Zitieren
APA
Abouda, A. B. (2024). Case Study: Cost Analysis and Emission and Analysis of a 100mw Grid-Connected Wind Energy System Using Retscreen Expert Simulation Software. Journal of Technology Research, 2(1), 1-6. https://doi.org/10.26629/jtr.2024.01
Vancouver
Abouda AB. Case Study: Cost Analysis and Emission and Analysis of a 100mw Grid-Connected Wind Energy System Using Retscreen Expert Simulation Software. Journal of Technology Research. 2024;2(1):1-6. doi:10.26629/jtr.2024.01
BibTeX
@article{Abouda2024,
author = {Abouda, Almotaz bellah},
title = {Case Study: Cost Analysis and Emission and Analysis of a 100mw Grid-Connected Wind Energy System Using Retscreen Expert Simulation Software},
journal = {Journal of Technology Research},
year = {2024},
volume = {2},
number = {1},
pages = {1--6},
doi = {10.26629/jtr.2024.01}
}
EUVIMED